Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Payables (2016 - 2025)

Kiora Pharmaceuticals' Payables history spans 11 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Payables rose 155.13% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.1 million, up 155.13%, while the annual FY2025 figure was $1.1 million, 155.13% up from the prior year.
  • Payables reached $1.1 million in Q4 2025 per KPRX's latest filing, up from $241471.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.1 million in Q4 2025 to a low of $125412.0 in Q3 2023.
  • Average Payables over 5 years is $443019.6, with a median of $323062.0 recorded in 2024.
  • Peak YoY movement for Payables: surged 613.69% in 2021, then plummeted 83.29% in 2023.
  • A 5-year view of Payables shows it stood at $160621.0 in 2021, then surged by 366.43% to $749192.0 in 2022, then plummeted by 72.47% to $206260.0 in 2023, then soared by 101.49% to $415590.0 in 2024, then soared by 155.13% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Payables are $1.1 million (Q4 2025), $241471.0 (Q3 2025), and $282537.0 (Q2 2025).